Model Identifier
BIOMD0000000575
Short description
Sass2009 - Approach to an α-synuclein-based BST model of Parkinson's disease

This model is described in the article:

Sass MB, Lorenz AN, Green RL, Coleman RA.
J. Neurosci. Methods 2009 Apr; 178(2): 366-377

Abstract:

This paper presents a detailed systems model of Parkinson's disease (PD), developed utilizing a pragmatic application of biochemical systems theory (BST) intended to assist experimentalists in the study of system behavior. This approach utilizes relative values as a reasonable initial estimate for BST and provides a theoretical means of applying numerical solutions to qualitative and semi-quantitative understandings of cellular pathways and mechanisms. The approach allows for the simulation of human disease through its ability to organize and integrate existing information about metabolic pathways without having a full quantitative description of those pathways, so that hypotheses about individual processes may be tested in a systems environment. Incorporating this method, the PD model describes alpha-synuclein aggregation as mediated by dopamine metabolism, the ubiquitin-proteasome system, and lysosomal degradation, allowing for the examination of dynamic pathway interactions and the evaluation of possible toxic mechanisms in the aggregation process. Four system perturbations: elevated alpha-synuclein aggregation, impaired dopamine packaging, increased neurotoxins, and alpha-synuclein overexpression, were analyzed for correlation to qualitative PD system hypotheses present in the literature, with the model demonstrating a high level of agreement with these hypotheses. Additionally, various PD treatment methods, including levadopa and monoamine oxidase inhibition (MAOI) therapy, were applied to the disease models to examine their effects on the system. Future additions and refinements to the model may further the understanding of the emergent behaviors of the disease, helping in the identification of system sensitivities and possible therapeutic targets.

To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide. Please refer to CC0 Public Domain Dedication for more information.

Format
SBML (L2V4)
Related Publication
  • A pragmatic approach to biochemical systems theory applied to an alpha-synuclein-based model of Parkinson's disease. Click here to expand
  • Matthew B Sass, Alyson N Lorenz, Robert L Green, Randolph A Coleman
  • Journal of neuroscience methods , 4/ 2009 , Volume 178 , Issue 2 , pages: 366-377 , PubMed ID: 19136028
  • Department of Chemistry, Integrated Science Center, The College of William and Mary, Williamsburg, VA 23187, USA.
  • This paper presents a detailed systems model of Parkinson's disease (PD), developed utilizing a pragmatic application of biochemical systems theory (BST) intended to assist experimentalists in the study of system behavior. This approach utilizes relative values as a reasonable initial estimate for BST and provides a theoretical means of applying numerical solutions to qualitative and semi-quantitative understandings of cellular pathways and mechanisms. The approach allows for the simulation of human disease through its ability to organize and integrate existing information about metabolic pathways without having a full quantitative description of those pathways, so that hypotheses about individual processes may be tested in a systems environment. Incorporating this method, the PD model describes alpha-synuclein aggregation as mediated by dopamine metabolism, the ubiquitin-proteasome system, and lysosomal degradation, allowing for the examination of dynamic pathway interactions and the evaluation of possible toxic mechanisms in the aggregation process. Four system perturbations: elevated alpha-synuclein aggregation, impaired dopamine packaging, increased neurotoxins, and alpha-synuclein overexpression, were analyzed for correlation to qualitative PD system hypotheses present in the literature, with the model demonstrating a high level of agreement with these hypotheses. Additionally, various PD treatment methods, including levadopa and monoamine oxidase inhibition (MAOI) therapy, were applied to the disease models to examine their effects on the system. Future additions and refinements to the model may further the understanding of the emergent behaviors of the disease, helping in the identification of system sensitivities and possible therapeutic targets.
Contributors
Submitter of the first revision: Audald Lloret i Villas
Submitter of this revision: Lucian Smith
Curator: Lucian Smith
Modellers: administrator, Audald Lloret i Villas

Metadata information

is (2 statements)
BioModels Database BIOMD0000000575
BioModels Database MODEL1504130001

isDescribedBy (1 statement)
PubMed 19136028

hasTaxon (1 statement)
Taxonomy Homo sapiens

isVersionOf (5 statements)
hasProperty (2 statements)
Human Disease Ontology Parkinson's disease
Mathematical Modelling Ontology Ordinary differential equation model


Curation status
Curated


Connected external resources